Urovant Sciences Ltd. UROV
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 531.75M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -3.09
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 12, 2021
- 50-d avg
- 16.21
- 200-d avg
- 13.98
- 1y target
- 16.17
News
4 years ago benzinga.com
Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo
Urovant Sciences' interim results from a Phase 2a trial of URO-902 gene therapy were presented at the annual meeting of the American Urological Association (AUA2022). Urovant is a wholly-owned…
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
Wednesday morning saw 162 companies set new 52-week highs.
5 years ago prnewswire.com
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies -UROV, INFO, WDR, CKH, EIGI
NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Urovant Sciences Ltd. (NASDAQ: UROV) concerning…
5 years ago globenewswire.com
Sumitovant Biopharma Announces Urovant Sciences Receives U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
GEMTESA® is the second FDA approval for the Sumitovant Biopharma family of companies in the past weekGEMTESA® is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the…
5 years ago businesswire.com
Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for…
5 years ago businesswire.com
UROVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Urovant Sciences - UROV
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Urovant…
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Thursday
During the morning session on Thursday, 53 stocks hit new 52-week highs.
5 years ago newsfilecorp.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Urovant Sciences Ltd. to Sumitovant Biopharma
New York, New York--(Newsfile Corp. - November 18, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please…
5 years ago prnewswire.com
RM LAW Announces Investigation of Urovant Sciences Ltd.
BERWYN, Pa., Nov. 18, 2020 /PRNewswire/ -- RM LAW, P.C. announces an investigation on behalf of Urovant Sciences Ltd. ("Urovant" or the "Company") (NASDAQ: UROV) regarding possible breaches of…
5 years ago seekingalpha.com
Urovant Sciences: Buyout Price Is Too Low
The acquisition of Urovant Sciences by majority owner Sumitomo significantly undervalues the company's lead asset vibegron. The buyout price implies approximately $250 million in peak sales for…
5 years ago prnewswire.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Urovant Sciences Ltd. - UROV
NEW YORK, Nov. 13, 2020 /PRNewswire/-- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York…
5 years ago prnewswire.com
SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd.
NEW YORK, Nov. 13, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. ("UROV" or the…
5 years ago fool.com
Why Urovant Sciences Stock Is Skyrocketing Today
The company's biggest shareholder plans to acquire all of Urovant.
5 years ago investorplace.com
UROV Stock: 9 Things to Know About the Urovant Sciences-Sumitovant Deal
Urovant Sciences (UROV) has entered into an acquisition agreement with Sumitovant Biopharma that has UROV stock soaring on Friday. The post UROV Stock: 9 Things to Know About the Urovant…
5 years ago businesswire.com
Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
5 years ago prnewswire.com
Sumitovant Biopharma and Urovant Sciences Announce Sumitovant's Acquisition of Remaining Stake in Urovant
NEW YORK and LONDON and IRVINE, Calif. and BASEL, Switzerland, Nov. 12, 2020 /PRNewswire/ -- Sumitovant Biopharma and Urovant Sciences (Nasdaq: UROV) today announced that they have entered into a…
6 years ago seekingalpha.com
Urovant Sciences' (UROV) CEO Jim Robinson on Q2 2020 Results - Earnings Call Transcript
Urovant Sciences' (UROV) CEO Jim Robinson on Q2 2020 Results - Earnings Call Transcript
6 years ago businesswire.com
Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that it will report financial results for its fiscal quarter ended September 30, 2020 after the…
6 years ago businesswire.com
Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that it will report 2020 first fiscal quarter financial results after the close of U.S. financial…
6 years ago seekingalpha.com
Urovant Sciences Ltd (UROV) CEO James Robinson on Q4 2019 Results - Earnings Call Transcript
Urovant Sciences Ltd (NASDAQ:UROV) Q4 2019 Earnings Conference Call June 18, 2020, 16:30 ET Company Participants Ryan Kubota - Executive Director, IR James Robi
6 years ago businesswire.com
Urovant Sciences to Report Fiscal Year and Fourth Quarter 2019 Results
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that it will report fiscal year and fourth quarter 2019 results after the close of U.S. financial…
6 years ago businesswire.com
Urovant Sciences to Report 2019 Third Fiscal Quarter Financial Results
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that it will report 2019 third fiscal quarter financial results after the close of U.S. financial…
-
7 years ago benzinga.com
45 Stocks Moving In Tuesday's Mid-Day Session
45 Stocks Moving In Tuesday's Mid-Day Session
-
7 years ago benzinga.com
45 Stocks Moving In Tuesday's Mid-Day Session
45 Stocks Moving In Tuesday's Mid-Day Session
-
7 years ago benzinga.com
Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018
Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018
-
7 years ago benzinga.com
Stocks Which Set New 52-Week Low Yesterday, Thurs., Nov. 16, 2018
Stocks Which Set New 52-Week Low Yesterday, Thurs., Nov. 16, 2018
-
7 years ago benzinga.com
Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 7, 2018
Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 7, 2018
-
8 years ago benzinga.com
Stocks Which Set New 52-Week High Yesterday, October 4th
Stocks Which Set New 52-Week High Yesterday, October 4th
-
8 years ago benzinga.com
Stocks Which Set New 52-Week High Yesterday, October 3rd
Stocks Which Set New 52-Week High Yesterday, October 3rd
-
8 years ago benzinga.com
Stocks Which Set New 52-Week High Yesterday, October 2nd
Stocks Which Set New 52-Week High Yesterday, October 2nd